Background. Studies have shown that patients with chronic renal failure have a high frequency of cardiocascular atheromatous disease.
in lipids of patients and controls were also studied (Table III) . In patient groups, serum Lp(a) levels were negatively correlated with serum HDL-C and apo A-1 levels, and positively correlated with TG, TC, LDL-C, VLDL-C, and apo B. In the controls, there were no significant relationships between serum Lp(a) and other lipid, lipoprotein, and apolipoprotein levels.
DISCUSSION
Our study conclusively demonstrates lipoprotein and lipid abnormalities associated with CRF in patients both on and off HD. The concentrations of TG and TC in serum were higher in both patient groups than those in the controls, and apo A-1 and HDL-C levels were lower in patients. These findings confirm previous reports in the literature. Roh12) reported that atherogenesis accelerates in HD patients. Cuxart et al.14) detected hypertriglyceridemia in 34% of HD patients. In the present study, the prevalence of hypertriglyceridemia (greater than 200mg/dl) was 20% and 16% in patients who were not on HD and were on HD, respectively. Schumaker et al.15) reported increased concentrations of serum TG and apo B in patients with CRF. Haaber et al.16) found that the plasma concentrations of lipoproteins showed an atherogenic pattern in CRF patients with increased levels of VLDL-C and TG, but a decreased level of HDL-C. According to the study of Kaysen,17) plasma TG is increased in the majority of patients with advanced renal failure but cholesterol is not. He also reported that the HDL-associated apolipoproteins apo A-1 and A-II are decreased, while apo B is increased in these patients. Segerra et al.9) reported that patients with CRF had lower serum levels of HDL-C and apo A-1, and higher TG and VLDL-C than did the control group. In the present study, apo B and LDL-C were similar in the patients treated by HD and controls.
Lipoprotein catabolic rate is reduced in patients with CRF, but the cause of hyperlipidemia is multifactorial; e.g. reduced lipoprotein lipase activity (LPL), increased concentration of apo C-III (a specific inhibitor of LPL) in plasma, secondary hyperparathyroidism, and insulin resistance.17-19) Horkko et al.20) reported that the clearance of LDL in patients with advanced uremia on conservative management is frequently decreased. These alterations in the metabolism of the most atherogenic particle in plasma or serum may contribute to the accelerated atherosclerosis in uremic patients. While atherosclerotic disease and thrombosis are the leading causes of death in dialysis patients, it is not certain that the specific lipid disorders of CRF are responsible for this morbidity, nor is it recommended at this time that qualitative abnormalities be treated pharmacologically in the absence of increased lipid levels.17,20) When hyperlipidemia is present, plasma newly-synthesized cholesteryl ester transfer rates are raised and may contribute to elevated levels of the proatherogenic apo B-containing lipoproteins in patients with renal failure.21) Querfeld et al.22) found that the distribution of Lp(a) levels in normal subjects was skewed to the left with 97% having levels less than 30mg/dl. All normal subjects in this study had serum Lp(a) levels below 30mg/dl. Cuxart et al.14) showed a higher prevalence of positive Lp(a) (greater than 30mg/dl) in the HD group. The number of high-Lp(a) level patients on HD was 14 (31%) in this study.
Cressman et al.23) found that patients on HD have four-fold higher Lp(a) levels in serum than those of controls. They suggested that dialysis has a negative effect on lipid metabolism.
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In this study, the ratios of apo B/apo A-1, LDL-C/HDL-C, and TC/HDL-C were higher in patients with CRF on HD as compared with controls. Also, patients who were not on HD had higher ratios of LDL-C/HDL-C and TC/ HDL-C. However, the ratio of apo B/apo A-1 in these patients was not different than that of the controls. We could not find similar reports in terms of these parameters in the literature.
There were significant correlations between Lp(a) and other parameters of lipid and lipoprotein metabolism in patients with CRF who were or not on HD in the present study. However, conflicting results about these relationships have been reported in previous studies.8,9,24-26) Segerra et al.9) reported that there was no relationship between Lp(a) and other parameters of lipoprotein metabolism, for example, apolipoproteins A1, B, C-II, and C-III, HDL-C and LDL-C in patients with CRF before renal transplantation. Thus, they concluded that the increase in Lp(a) during the CRF phase is basically related to the loss of renal function and does not depend on the resultant alterations which are produced in other lipoprotein variables. Takegoshi et al.25) found a statistically significant correlation of Lp(a) with serum lipoprotein and apolipoprotein levels in patients with CRY treated by continuous ambulatory peritoneal dialysis (CAPD). Hoffner et al.8) reported that Lp(a) levels were not correlated with the level of creatinine in subjects with CRF. Thus, the elevation of Lp(a) levels in renal failure must occur early in renal failure, or alternatively, elevated Lp(a) levels may promote progression to CRY However, the cause of the controversial results may stem from the different study groups in our study and the above studies. Our results indicate that increased serum Lp(a) together with other lipoprotein abnormalities in patients with CRF who were and were not on HD imply an increased cardiovascular risk, and that there were significant relationships between Lp(a) and other parameters of lipoprotein metabolism such as TG, TC, HDL-C, LDL-C, VLDL-C, apo A-1 and apo B.
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